[go: up one dir, main page]

SG11201503640WA - Transmucosal delivery of tocotrienol - Google Patents

Transmucosal delivery of tocotrienol

Info

Publication number
SG11201503640WA
SG11201503640WA SG11201503640WA SG11201503640WA SG11201503640WA SG 11201503640W A SG11201503640W A SG 11201503640WA SG 11201503640W A SG11201503640W A SG 11201503640WA SG 11201503640W A SG11201503640W A SG 11201503640WA SG 11201503640W A SG11201503640W A SG 11201503640WA
Authority
SG
Singapore
Prior art keywords
tocotrienol
transmucosal delivery
transmucosal
delivery
Prior art date
Application number
SG11201503640WA
Inventor
Glenn Tong
Original Assignee
Gordagen Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904937A external-priority patent/AU2012904937A0/en
Application filed by Gordagen Pharmaceuticals Pty Ltd filed Critical Gordagen Pharmaceuticals Pty Ltd
Publication of SG11201503640WA publication Critical patent/SG11201503640WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201503640WA 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol SG11201503640WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904937A AU2012904937A0 (en) 2012-11-13 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
AU2012905406A AU2012905406A0 (en) 2012-12-11 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
PCT/AU2013/001310 WO2014075135A1 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Publications (1)

Publication Number Publication Date
SG11201503640WA true SG11201503640WA (en) 2015-06-29

Family

ID=50730398

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503640WA SG11201503640WA (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Country Status (22)

Country Link
US (2) US10675265B2 (en)
EP (1) EP2919777B1 (en)
JP (3) JP6460998B2 (en)
KR (1) KR20150082109A (en)
CN (2) CN112451518B (en)
AU (1) AU2013344817B2 (en)
BR (1) BR112015010703B1 (en)
CA (1) CA2891164C (en)
DK (1) DK2919777T3 (en)
ES (1) ES2778065T3 (en)
IL (1) IL238727A0 (en)
IN (1) IN2015DN04006A (en)
MY (1) MY177940A (en)
NZ (1) NZ628963A (en)
PE (1) PE20151518A1 (en)
PH (1) PH12015501048A1 (en)
PL (1) PL2919777T3 (en)
PT (1) PT2919777T (en)
RU (1) RU2015120181A (en)
SG (1) SG11201503640WA (en)
WO (1) WO2014075135A1 (en)
ZA (1) ZA201504191B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
CN112451518B (en) * 2012-11-13 2025-02-21 因维克特斯生物技术有限公司 Transmucosal delivery of tocotrienols
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3050023B1 (en) 2014-10-27 2021-08-25 Aseko, Inc. Subcutaneous outpatient management
JP2018522950A (en) * 2015-08-11 2018-08-16 杉山 理 Systems and methods for improving blood circulation and maintaining mitochondrial energy production
WO2017031440A1 (en) 2015-08-20 2017-02-23 Aseko, Inc. Diabetes management therapy advisor
US11612613B2 (en) 2017-08-08 2023-03-28 Robert Petcavich Formulations for the delivery of autophagy stimulating Trehalose
US20240139100A1 (en) * 2020-12-04 2024-05-02 Invictus Biotechnology Pty Ltd Transmucosal delivery of tocotrienols

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124086A1 (en) * 1991-11-22 1993-05-27 Ronald H. Lane Tocotrienols and tocotrienol-like compounds and methods for their use
JPH0892050A (en) 1994-09-27 1996-04-09 Lion Corp Deodorant and oral composition
JP4271742B2 (en) 1997-08-07 2009-06-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 Immune function improving agent
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DE60142330D1 (en) * 2000-03-31 2010-07-22 Eisai R&D Man Co Ltd USE OF GAMMA TOCOTRIENOL AS DIURETICS
JP2001342133A (en) 2000-03-31 2001-12-11 Eisai Co Ltd gamma-TOCOTRIENOL-CONTAINING DIURETIC
JP2002037727A (en) 2000-07-26 2002-02-06 Eisai Co Ltd Lipid-soluble medicine-formulated rapid disintegrable solid pharmaceutical preparation and method for producing the same
JP4693140B2 (en) * 2000-10-06 2011-06-01 富士化学工業株式会社 Tocotrienol-containing pharmaceutical agent
JP4447198B2 (en) 2001-02-08 2010-04-07 富士化学工業株式会社 Angiogenesis inhibitor, cell growth inhibitor, tube formation inhibitor, FGF inhibitor and food or food additive containing tocotrienol as an active ingredient
US6608103B2 (en) * 2001-02-08 2003-08-19 Fuji Chemical Industry Co., Ltd. Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
EP1593127B1 (en) 2003-02-14 2012-06-06 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Radiation protection by gamma-tocotrienol, alpha-tocopherol succinate or gamma-tocopherol succinate
EP1617724B1 (en) * 2003-04-10 2014-08-20 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
US20050209315A1 (en) * 2004-03-20 2005-09-22 Papas Andreas M Bioavailable nutritional supplement and method of treatment of malabsorption
ZA200610168B (en) * 2004-05-26 2008-06-25 Kgk Synergize Inc Compositions comprising flavonoids and tocotrienols and methods thereof
CN1775289B (en) 2004-11-15 2011-08-24 杭州赛诺菲民生健康药业有限公司 Multi-vitamin orally disintegrating tablet preparation and preparation method thereof
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2009126866A2 (en) * 2008-04-10 2009-10-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Delta-tocotrienol as a radioprotective countermeasure agent
MX2011012078A (en) 2009-05-20 2012-03-14 Lingual Consegna Pty Ltd Buccal and/or sublingual therapeutic formulation.
EP2609921A1 (en) * 2009-06-25 2013-07-03 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
CA2772294C (en) * 2009-08-26 2018-08-21 Guy M. Miller Methods for the prevention and treatment of cerebral ischemia
CA2797644A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011126998A1 (en) * 2010-04-06 2011-10-13 Edison Pharmaceuticals, Inc. Treatment of ataxia telangiectasia
US20120295985A1 (en) 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control
MX359670B (en) 2011-02-18 2018-10-05 Biolingus Ip Llc Process for preparing products comprising stabilised actives and compositions comprising same.
PL3415139T3 (en) 2011-06-14 2022-07-11 Neurelis, Inc. Administration of benzodiazepine
CN112451518B (en) * 2012-11-13 2025-02-21 因维克特斯生物技术有限公司 Transmucosal delivery of tocotrienols

Also Published As

Publication number Publication date
AU2013344817B2 (en) 2015-09-17
US20200246306A1 (en) 2020-08-06
EP2919777A4 (en) 2016-05-18
ZA201504191B (en) 2016-11-30
CN112451518B (en) 2025-02-21
NZ628963A (en) 2017-02-24
CN104582700B (en) 2021-01-05
PH12015501048A1 (en) 2015-07-27
BR112015010703A2 (en) 2017-07-11
PE20151518A1 (en) 2015-11-25
BR112015010703A8 (en) 2018-08-14
EP2919777A1 (en) 2015-09-23
PT2919777T (en) 2020-03-30
CN112451518A (en) 2021-03-09
CA2891164A1 (en) 2014-05-22
JP2016503407A (en) 2016-02-04
RU2015120181A (en) 2017-01-10
WO2014075135A1 (en) 2014-05-22
PL2919777T3 (en) 2020-07-13
JP2019031504A (en) 2019-02-28
US20150265570A1 (en) 2015-09-24
AU2013344817A1 (en) 2015-02-12
JP6978392B2 (en) 2021-12-08
CA2891164C (en) 2021-02-09
ES2778065T3 (en) 2020-08-07
IN2015DN04006A (en) 2015-10-02
EP2919777B1 (en) 2020-01-08
JP2021008509A (en) 2021-01-28
DK2919777T3 (en) 2020-03-09
HK1207295A1 (en) 2016-01-29
US10675265B2 (en) 2020-06-09
KR20150082109A (en) 2015-07-15
IL238727A0 (en) 2015-06-30
JP6460998B2 (en) 2019-01-30
MY177940A (en) 2020-09-28
CN104582700A (en) 2015-04-29
BR112015010703B1 (en) 2021-02-17
US11331302B2 (en) 2022-05-17

Similar Documents

Publication Publication Date Title
ZA201504191B (en) Transmucosal delivery of tocotrienol
IL236268A0 (en) Compositions for transmucosal delivery and uses thereof
GB2503668B (en) Delivery apparatus
GB201213491D0 (en) Content delivery system
GB2507485B (en) Lead delivery apparatus
ZA201505049B (en) Transmucosal delivery of glatiramer acetate
EP2829537A4 (en) Chromene compound
SG10201609440WA (en) Multi-additive delivery system
PL2908837T3 (en) Compositions for drug delivery
EP2911420A4 (en) Content delivery method
GB201218012D0 (en) Dosage forms
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
AU344422S (en) Nebulizer
EP2839418A4 (en) Lottery promotion
HUE12715191T1 (en) Vitrified sintered product
HK40048338B (en) Transmucosal delivery of tocotrienols
GB201208751D0 (en) Anti-malarial compounds
PH32012000655S1 (en) Sock
TWM433160U (en) Cup structure improvement
GB201216518D0 (en) Convienance cup
GB201210511D0 (en) Parcel delivery solution
AU346861S (en) Bracket
AU345987S (en) Bracket
GB201220136D0 (en) Anti-ligature Bracket
AU345981S (en) Bracket